AR076360A1 - Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer - Google Patents
Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancerInfo
- Publication number
- AR076360A1 AR076360A1 ARP100101317A ARP100101317A AR076360A1 AR 076360 A1 AR076360 A1 AR 076360A1 AR P100101317 A ARP100101317 A AR P100101317A AR P100101317 A ARP100101317 A AR P100101317A AR 076360 A1 AR076360 A1 AR 076360A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- substituted
- cycloalkyl
- espiroindolinona
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Estos compuestos tienen utilidad como agentes antiproliferativos, en especial como agentes anticancerosos, por ser inhibidores de la interaccion MDM2-p53. Reivindicacion 1: Un compuesto de la formula (1) en la que X es Cl, F o Br, Y es hidrogeno o F, V es F o Cl, V' es hidrogeno o F, Vö es hidrogeno o F, W es F, Cl o Br, W' es hidrogeno o F, R1 y R2 son hidrogeno, metilo, etilo o propilo, o R1 y R2 pueden unirse para formar una estructura cíclica elegida entre un cicloalquilo sustituido o sin sustituir; R3 se elige entre OH, OR', NH2, NHR', NR'Rö, NHOR' y -NHS(=O)2Rö, R', Rö se eligen con independencia entre el grupo formado por alquilo inferior, alquilo sustituido, cicloalquilo y cicloalquilo sustituido, y las sales, ésteres y enantiomeros farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17197009P | 2009-04-23 | 2009-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076360A1 true AR076360A1 (es) | 2011-06-08 |
Family
ID=42281205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101317A AR076360A1 (es) | 2009-04-23 | 2010-04-21 | Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer |
Country Status (9)
Country | Link |
---|---|
US (1) | US8076482B2 (es) |
EP (1) | EP2421866A1 (es) |
JP (1) | JP2012524745A (es) |
CN (1) | CN102459266A (es) |
AR (1) | AR076360A1 (es) |
CA (1) | CA2758640A1 (es) |
SG (1) | SG175756A1 (es) |
TW (1) | TW201041890A (es) |
WO (1) | WO2010121995A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5649825B2 (ja) * | 2007-01-31 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 安定化させたp53ペプチドおよびその使用法 |
ES2430067T3 (es) | 2007-03-28 | 2013-11-18 | President And Fellows Of Harvard College | Polipéptidos cosidos |
KR20120099462A (ko) | 2009-11-12 | 2012-09-10 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | 스피로-옥신돌 mdm2 길항제 |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
KR20170058446A (ko) | 2010-08-13 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
SG190230A1 (en) | 2010-11-12 | 2013-06-28 | Univ Michigan | Spiro-oxindole mdm2 antagonists |
US8629133B2 (en) | 2011-03-10 | 2014-01-14 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivatives |
SG194873A1 (en) | 2011-05-11 | 2013-12-30 | Sanofi Sa | Spiro-oxindole mdm2 antagonists |
US9376425B2 (en) | 2011-09-27 | 2016-06-28 | Amgen, Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
RU2639523C2 (ru) | 2011-10-18 | 2017-12-21 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы и их применение |
CA2862038C (en) | 2012-02-15 | 2021-05-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
JP6526563B2 (ja) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス,インコーポレイテッド | 二置換アミノ酸ならびにその調製および使用の方法 |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
WO2014134201A1 (en) | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
CA2906538C (en) | 2013-03-14 | 2021-02-02 | Ana Gonzalez Buenrostro | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
AU2015247646B2 (en) * | 2014-04-17 | 2019-06-06 | The Regents Of The University Of Michigan | MDM2 inhibitors and therapeutic methods using the same |
WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
WO2016026937A1 (en) | 2014-08-21 | 2016-02-25 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
MX2017003797A (es) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
CA2961029A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
TWI711452B (zh) | 2015-02-20 | 2020-12-01 | 日商第一三共股份有限公司 | 癌症的倂用治療法 |
CN107614003A (zh) | 2015-03-20 | 2018-01-19 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
EP3284466A4 (en) | 2015-04-13 | 2018-12-05 | Daiichi Sankyo Company, Limited | Treatment method combining mdm2 inhibitor and btk inhibitor |
US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
PE20181205A1 (es) | 2015-10-09 | 2018-07-23 | Boehringer Ingelheim Int | Nuevos compuestos de espiro[3h-indol-3,2'-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53 |
PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
JPWO2018074387A1 (ja) | 2016-10-17 | 2019-08-08 | 第一三共株式会社 | Mdm2阻害剤とdnaメチルトランスフェラーゼ阻害剤との併用治療法 |
EP3511334A1 (en) * | 2018-01-16 | 2019-07-17 | Adamed sp. z o.o. | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53 |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3714473A1 (de) | 1987-04-30 | 1988-11-10 | Basf Ag | Kontinuierliches verfahren zur epimerisierung von zuckern, insbesondere von d-arabinose zu d-ribose |
EP0947511A1 (en) | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity |
NZ516452A (en) | 1999-07-21 | 2004-06-25 | Astrazeneca Ab | Spirooxindole Derivatives |
CN101160314B (zh) | 2005-02-22 | 2012-05-23 | 密执安州立大学董事会 | Mdm2的小分子抑制剂以及其应用 |
JP2009530236A (ja) | 2006-03-13 | 2009-08-27 | エフ.ホフマン−ラ ロシュ アーゲー | スピロインドリノン誘導体 |
US7495007B2 (en) | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
CA2656398A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
US7638548B2 (en) | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
WO2008080822A1 (en) | 2006-12-29 | 2008-07-10 | F. Hoffmann-La Roche Ag | Epimerization methodologies for recovering stereo isomers in high yield and purity |
US7553833B2 (en) | 2007-05-17 | 2009-06-30 | Hoffmann-La Roche Inc. | 3,3-spiroindolinone derivatives |
US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
US20100190814A1 (en) * | 2009-01-26 | 2010-07-29 | Li Chen | Spiroindolinone derivative prodrugs |
-
2010
- 2010-03-29 US US12/748,687 patent/US8076482B2/en not_active Expired - Fee Related
- 2010-04-20 WO PCT/EP2010/055139 patent/WO2010121995A1/en active Application Filing
- 2010-04-20 CN CN2010800325408A patent/CN102459266A/zh active Pending
- 2010-04-20 JP JP2012506457A patent/JP2012524745A/ja active Pending
- 2010-04-20 TW TW099112381A patent/TW201041890A/zh unknown
- 2010-04-20 EP EP10716316A patent/EP2421866A1/en not_active Withdrawn
- 2010-04-20 SG SG2011076890A patent/SG175756A1/en unknown
- 2010-04-20 CA CA2758640A patent/CA2758640A1/en not_active Abandoned
- 2010-04-21 AR ARP100101317A patent/AR076360A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW201041890A (en) | 2010-12-01 |
JP2012524745A (ja) | 2012-10-18 |
EP2421866A1 (en) | 2012-02-29 |
CN102459266A (zh) | 2012-05-16 |
US20100273819A1 (en) | 2010-10-28 |
US8076482B2 (en) | 2011-12-13 |
SG175756A1 (en) | 2011-12-29 |
CA2758640A1 (en) | 2010-10-28 |
WO2010121995A1 (en) | 2010-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076360A1 (es) | Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer | |
ECSP12012292A (es) | Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos | |
AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
SV2011003853A (es) | Compuestos organicos | |
ECSP11010898A (es) | Pirrolidina-2-carboxamidas sustituidas | |
ECSP10010556A (es) | Piridinas y pirazinas como inhibidores de pi3k | |
PE20130010A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih | |
PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
PE20150128A1 (es) | Moduladores del transporte nuclear y usos de los mismos | |
AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
AR078151A1 (es) | Conjugados de acidos grasos y niacina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades metabolicas. | |
AR075243A1 (es) | Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa | |
CU20110216A7 (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
GT201200322A (es) | Derivados de carbamato de hexafluoroisoprofilo, su preparacion y su aplicacion en terapeutica | |
CO6290658A2 (es) | Derivados de azetidina y ciclobutano como inhibidores de jack | |
PE20131464A1 (es) | Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa | |
UY33731A (es) | ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep? | |
DOP2011000260A (es) | Pirimidinas fusionadas | |
AR070352A1 (es) | Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto. | |
AR073603A1 (es) | Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido | |
PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |